Page last updated: 2024-08-23

etoposide and mk 2206

etoposide has been researched along with mk 2206 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Attayan, N; Li, Z; Ramalingam, S; Thiele, CJ; Yan, S	1

Other Studies

1 other study(ies) available for etoposide and mk 2206

Article	Year
Combination of an allosteric Akt Inhibitor MK-2206 with etoposide or rapamycin enhances the antitumor growth effect in neuroblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Jul-01, Volume: 18, Issue:13 Topics: Allosteric Regulation; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Etoposide; Female; Heterocyclic Compounds, 3-Ring; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Neuroblastoma; Phosphorylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Sirolimus; Tumor Burden; Xenograft Model Antitumor Assays	2012

Article

Year

Combination of an allosteric Akt Inhibitor MK-2206 with etoposide or rapamycin enhances the antitumor growth effect in neuroblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Jul-01, Volume: 18, Issue:13

Topics: Allosteric Regulation; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Etoposide; Female; Heterocyclic Compounds, 3-Ring; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Neuroblastoma; Phosphorylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Sirolimus; Tumor Burden; Xenograft Model Antitumor Assays

2012